PE20100851A1 - PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk - Google Patents
PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE BtkInfo
- Publication number
- PE20100851A1 PE20100851A1 PE2010001046A PE2010001046A PE20100851A1 PE 20100851 A1 PE20100851 A1 PE 20100851A1 PE 2010001046 A PE2010001046 A PE 2010001046A PE 2010001046 A PE2010001046 A PE 2010001046A PE 20100851 A1 PE20100851 A1 PE 20100851A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pyridin
- halogen
- methyl
- onas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRIDIN-2-ONA O PIRIDAZIN-3-ONA DE FORMULAS I, II, III Y IV, DONDE R ES H, R1, R1-R2-R3, R1-R3 O R2-R3; R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES C(=O), C(=O)O, (CH2)q, ENTRE OTROS; q ES 1, 2 O 3; R1 ES ALQUILO C1-C10, OH, HIDROXIALQUILO C1-C10, ENTRE OTROS; R3 ES H O R4; R4 ES ALQUILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS; X ES CH O N; Y1 ES H O ALQUILO C1-C10; Y2 ES Y2a O Y2b; Y2a ES H O HALOGENO; Y2b ES ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON Y2b'; Y2b' ES OH, ALCOXI, HALOGENO; Y2' ES Y2'a O Y2'b; Y2'a ES HALOGENO; Y2'b ES ALQUILO C1-C10, ENTRE OTROS; n ES UN ENTERO DE 0 A 3; Y3 ES H, HALOGENO, ALQUILO C1-C10; ENTRE OTROS; Y4 ES Y4a, Y4b, Y4c O Y4d; Y4a ES H O HALOGENO; Y4b ES ALQUILO C1-C10, ENTRE OTROS; Y4c ES CICLOALQUILO; Y4d ES AMINO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C10. SON COMPUESTOS PREFERIDOS: 1-{5-[3-(7-TERT-BUTIL-4-OXO-4H-QUINAZOLIN-3-IL)-2-METIL-FENIL]-1-METIL-2-OXO-1,2-DIHIDRO-PIRIDIN-3-IL}-3-METIL-UREA, 7-DIMETILAMINO-3-(2-METIL-3-{1-METIL-5-[5-(MORFOLINA-4-CARBONIL)-PIRIDIN-2-ILAMINO]-6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL}-FENIL)-3H-QUINAZOLIN-4-ONA, ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA TIROSINA-QUINASA DE BRUTON (Btk) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES E INFLAMATORIAS CAUSADAS POR LA ACTIVACION DE CELULAS B
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7527708P | 2008-06-24 | 2008-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20100851A1 true PE20100851A1 (es) | 2011-01-31 |
Family
ID=40972952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010001046A PE20100851A1 (es) | 2008-06-24 | 2009-06-15 | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk |
Country Status (25)
Country | Link |
---|---|
US (4) | US7902194B2 (es) |
EP (1) | EP2297142B1 (es) |
JP (1) | JP5536049B2 (es) |
KR (1) | KR101299867B1 (es) |
CN (3) | CN102066366B (es) |
AR (1) | AR072272A1 (es) |
AU (1) | AU2009264400B2 (es) |
BR (1) | BRPI0914657A2 (es) |
CA (1) | CA2728016C (es) |
CL (1) | CL2010001483A1 (es) |
CO (1) | CO6382183A2 (es) |
CR (1) | CR11815A (es) |
EC (1) | ECSP10010709A (es) |
ES (1) | ES2552320T3 (es) |
HK (2) | HK1152940A1 (es) |
IL (1) | IL209141A0 (es) |
MA (1) | MA32487B1 (es) |
MX (1) | MX2010013191A (es) |
NZ (2) | NZ588819A (es) |
PE (1) | PE20100851A1 (es) |
RU (1) | RU2500680C2 (es) |
TW (1) | TWI396537B (es) |
UA (1) | UA103327C2 (es) |
WO (1) | WO2009156284A1 (es) |
ZA (1) | ZA201007816B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
PE20110164A1 (es) * | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2513915T3 (es) * | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
CA3034600C (en) * | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
ES2537190T3 (es) * | 2010-09-01 | 2015-06-03 | Gilead Connecticut, Inc. | Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas |
CA2841801A1 (en) * | 2011-08-17 | 2013-02-21 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
JP5808869B2 (ja) * | 2011-11-03 | 2015-11-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二環式ピペラジン化合物 |
AR088642A1 (es) | 2011-11-03 | 2014-06-25 | Genentech Inc | Compuestos de piperazina alquilados |
JP5976826B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Btk活性阻害剤としての8−フルオロフタラジン−1(2h)−オン化合物 |
CA2854603A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
AU2013299557B2 (en) | 2012-08-10 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors |
US9499548B2 (en) * | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
EP2920162B1 (en) * | 2012-11-16 | 2017-04-19 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
WO2014135470A1 (en) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
WO2015000949A1 (en) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
PT3027618T (pt) | 2013-07-30 | 2020-10-12 | Kronos Bio Inc | Polimorfo de inibidores de syk |
CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
MX2016007171A (es) | 2013-12-05 | 2016-09-08 | Hoffmann La Roche | Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila. |
CN105793252B (zh) * | 2013-12-13 | 2018-01-30 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
WO2017123695A1 (en) * | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
US20190105407A1 (en) | 2016-03-31 | 2019-04-11 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
CA3037364A1 (en) | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
WO2020172431A1 (en) | 2019-02-22 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506856A (ja) * | 1998-03-14 | 2002-03-05 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | フタラジノンpdeiii/iv阻害剤 |
CA2375734A1 (en) * | 1999-06-03 | 2000-12-14 | Knoll Gmbh | Benzothiazinone and benzoxazinone compounds |
DZ3223A1 (fr) * | 1999-10-19 | 2001-04-26 | Merck & Co Inc | Inhibiteurs de tyrosine kinases |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
ES2543607T3 (es) * | 2005-03-10 | 2015-08-20 | Gilead Connecticut, Inc. | Ciertas amidas sustituidas, método de obtención, y método de su uso |
WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
DE602006017281D1 (de) | 2005-08-09 | 2010-11-11 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren |
JP2009507792A (ja) * | 2005-08-29 | 2009-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン |
EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
JP2009506123A (ja) | 2005-08-29 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン |
CN101405001A (zh) * | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
BRPI0711628A2 (pt) * | 2006-05-15 | 2011-12-06 | Irm Llc | composto, composição farmacêutica, uso e processo para preparação do composto |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
AR063707A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. |
EP2068849A2 (en) | 2006-09-11 | 2009-06-17 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
CA2909988A1 (en) * | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA2710462C (en) | 2008-02-05 | 2015-11-24 | F. Hoffmann-La Roche Ag | Pyridinones and pyridazinones |
-
2009
- 2009-06-15 PE PE2010001046A patent/PE20100851A1/es not_active Application Discontinuation
- 2009-06-15 CN CN200980123734.6A patent/CN102066366B/zh not_active Expired - Fee Related
- 2009-06-15 EP EP09769133.1A patent/EP2297142B1/en active Active
- 2009-06-15 MX MX2010013191A patent/MX2010013191A/es active IP Right Grant
- 2009-06-15 WO PCT/EP2009/057320 patent/WO2009156284A1/en active Application Filing
- 2009-06-15 ES ES09769133.1T patent/ES2552320T3/es active Active
- 2009-06-15 CN CN201310740898.1A patent/CN103709148B/zh not_active Expired - Fee Related
- 2009-06-15 NZ NZ588819A patent/NZ588819A/xx not_active IP Right Cessation
- 2009-06-15 CA CA2728016A patent/CA2728016C/en not_active Expired - Fee Related
- 2009-06-15 RU RU2011101774/04A patent/RU2500680C2/ru not_active IP Right Cessation
- 2009-06-15 UA UAA201100578A patent/UA103327C2/ru unknown
- 2009-06-15 KR KR1020107029040A patent/KR101299867B1/ko not_active IP Right Cessation
- 2009-06-15 BR BRPI0914657A patent/BRPI0914657A2/pt not_active IP Right Cessation
- 2009-06-15 CN CN201310343743.4A patent/CN103408533B/zh not_active Expired - Fee Related
- 2009-06-15 JP JP2011514004A patent/JP5536049B2/ja not_active Expired - Fee Related
- 2009-06-15 AU AU2009264400A patent/AU2009264400B2/en not_active Expired - Fee Related
- 2009-06-15 NZ NZ601700A patent/NZ601700A/xx not_active IP Right Cessation
- 2009-06-22 AR ARP090102276A patent/AR072272A1/es not_active Application Discontinuation
- 2009-06-23 TW TW098121074A patent/TWI396537B/zh not_active IP Right Cessation
- 2009-06-24 US US12/456,911 patent/US7902194B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 CO CO10132213A patent/CO6382183A2/es active IP Right Grant
- 2010-11-01 ZA ZA2010/07816A patent/ZA201007816B/en unknown
- 2010-11-04 IL IL209141A patent/IL209141A0/en unknown
- 2010-11-25 CR CR11815A patent/CR11815A/es not_active Application Discontinuation
- 2010-12-20 CL CL2010001483A patent/CL2010001483A1/es unknown
- 2010-12-23 EC EC2010010709A patent/ECSP10010709A/es unknown
-
2011
- 2011-01-10 US US12/987,187 patent/US8124604B2/en not_active Expired - Fee Related
- 2011-01-18 MA MA33534A patent/MA32487B1/fr unknown
- 2011-07-08 HK HK11107060.7A patent/HK1152940A1/xx not_active IP Right Cessation
-
2012
- 2012-01-26 US US13/358,557 patent/US8618098B2/en not_active Expired - Fee Related
-
2013
- 2013-09-11 US US14/024,354 patent/US8822457B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 HK HK14109767.6A patent/HK1196358A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20100851A1 (es) | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk | |
PE20091484A1 (es) | PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk | |
PE20110164A1 (es) | Nuevas fenilpirazinonas como inhibidores de quinasa | |
PE20081238A1 (es) | Piperidinas sustituidas como antagonistas de hdm2 | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20090449A1 (es) | Agonistas de receptor acoplado a proteina g gpr119 de piridona | |
PE20140865A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20141681A1 (es) | Inhibidores de btk | |
EA200870460A1 (ru) | Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20080405A1 (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb | |
PE20081532A1 (es) | Compuestos novedosos | |
EA200870521A1 (ru) | Замещенные спироциклические антагонисты cgrp-рецепторов | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
CO5570665A2 (es) | Novedosos derivados de piperidina como moduladores del recep tor quimocina ccrs | |
DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
PE20081375A1 (es) | Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5 | |
EA200900635A1 (ru) | Антагонисты прогестеронового рецептора | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |